Last reviewed · How we verify
Enzalutamide, Abiraterone
This combination of an androgen receptor antagonist (enzalutamide) and a CYP17A1 inhibitor (abiraterone) blocks testosterone production and androgen signaling to treat hormone-sensitive prostate cancer.
This combination of an androgen receptor antagonist (enzalutamide) and a CYP17A1 inhibitor (abiraterone) blocks testosterone production and androgen signaling to treat hormone-sensitive prostate cancer. Used for Metastatic castration-resistant prostate cancer (mCRPC), Metastatic hormone-sensitive prostate cancer (mHSPC).
At a glance
| Generic name | Enzalutamide, Abiraterone |
|---|---|
| Also known as | XTANDI, Zytiga |
| Sponsor | Veru Inc. |
| Drug class | Androgen receptor antagonist + CYP17A1 inhibitor combination |
| Target | Androgen receptor (AR) and CYP17A1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Enzalutamide competitively inhibits androgen receptor binding and nuclear translocation, while abiraterone acetate inhibits the CYP17A1 enzyme required for testosterone synthesis in the adrenal glands and tumor microenvironment. Together, they provide dual suppression of androgen-driven prostate cancer growth through complementary mechanisms.
Approved indications
- Metastatic castration-resistant prostate cancer (mCRPC)
- Metastatic hormone-sensitive prostate cancer (mHSPC)
Common side effects
- Fatigue
- Hot flashes
- Hypertension
- Hypokalemia
- Elevated liver enzymes
- Diarrhea
Key clinical trials
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (PHASE1, PHASE2)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (PHASE3)
- A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer (PHASE1, PHASE2)
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PHASE3)
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (PHASE3)
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enzalutamide, Abiraterone CI brief — competitive landscape report
- Enzalutamide, Abiraterone updates RSS · CI watch RSS
- Veru Inc. portfolio CI